Cytogenetic and molecular genetic changes in malignant mesothelioma

Cancer Genetics and Cytogenetics

Volumn 170, Issue 1, 2006, Pages 9-15

  Musti, Marina ^a   Kettunen, Eeva ^b   Dragonieri, Silvano ^c   Lindholm, Pamela ^d   Cavone, Domenica ^c   Serio, Gabriella ^c   Knuutila, Sakari ^d  

^a Section of Occupational Medicine   (Italy)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS FIBER;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CDKN2A GENE; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CHROMOSOME DELETION; CYTOGENETICS; DEVELOPING COUNTRY; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; DRUG TARGETING; GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE MUTATION; HEALTH SURVEY; HUMAN; LUNG CANCER; MALIGNANT MESOTHELIOMA; MOLECULAR GENETICS; NF2 GENE; OCCUPATIONAL EXPOSURE; PRECANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ASBESTOS; CHROMOSOME DELETION; DNA DAMAGE; GENES, P16; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; MESOTHELIOMA;

EID: 33748444562     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.04.011     Document Type: Article

References (120)

1. Ascoli V., Aalto Y., Carnovale-Scalzo C., Nardi F., Falzetti D., Mecucci C., and Knuutila S. DNA copy number changes in familial malignant mesothelioma. Cancer Genet Cytogenet 127 (2001) 80-82
2. Roushdy-Hammady I., Siegel J., Emri S., Testa J.R., and Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357 (2001) 444-445
3. Musti M., Cavone D., Aalto Y., Scattone A., Serio G., and Knuutila S. A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. Cancer Genet Cytogenet 138 (2002) 73-76
4. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 (1960) 260-271
5. Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 56 (1999) 505-513
6. Serio G., Scattone A., Gentile M., Nazzaro P., Pennella A., Buonadonna A.L., Pollice L., and Musti M. Familial pleural mesothelioma with environmental asbestos exposure: losses of DNA sequences by comparative genomic hybridization (CGH). Histopathology 45 (2004) 643-645
7. Hiyama J., Marukawa M., Shiota Y., Ono T., Imai S., Motohiro K., Aoki J., Sasaki N., Taniyama K., and Mashiba H. Two familial mesothelioma cases with high concentrations of soluble cytokeratin 19 fragment in pleural fluid. Intern Med 37 (1998) 407-410
8. Ascoli V., Carnovale-Scalzo C., Nardi F., Efrati C., and Menegozzo M. A one-generation cluster of malignant mesothelioma within a family reveals exposure to asbestos-contaminated jute bags in Naples, Italy. Eur J Epidemiol 18 (2003) 171-174
9. Bianchi C., Brollo A., Ramani L., Bianchi T., and Giarelli L. Familial mesothelioma of the pleura-a report of 40 cases. Ind Health 42 (2004) 235-239
10. Testa J.R., Carbone M., Hirvonen A., Khalili K., Krynska B., Linnainmaa K., Pooley F.D., Rizzo P., Rusch V., and Xiao G.H. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 58 (1998) 4505-4509
11. Shivapurkar N., Virmani A.K., Wistuba II, Milchgrub S., Mackay B., Minna J.D., and Gadzar A.F. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 5 (1999) 17-23
12. Carbone M., Kratzke R.A., and Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 29 (2002) 2-17
13. Puntoni R., Filiberti R., Cerrano P.G., Neri M., Andreatta R., and Bonassi S. Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma. Mutat Res 544 (2003) 385-396
14. Cristaudo A., Foddis R., Vivaldi A., Buselli R., Gattini V., Guglielmi G., Cosentino F., Ottenga F., Ciancia E., Libener R., Filiberti R., Neri M., Betta P., Tognon M., Mutti L., and Puntoni R. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 65 (2005) 3049-3052
15. Manfredi J.J., Dong J., Liu W.J., Resnick-Silverman L., Qiao R., Chahinian P., Saric M., Gibbs A.R., Phillips J.I., Murray J., Axten C.W., Nolan R.P., and Aaronson S.A. Evidence against a role for SV40 in human mesothelioma. Cancer Res 65 (2005) 2602-2609
16. Testa J.R., and Giordano A. SV40 and cell cycle perturbations in malignant mesothelioma. Semin Cancer Biol 11 (2001) 31-38
17. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 49 Suppl 1 (2005) S95-S98
18. Huncharek M. Genetic factors in the aetiology of malignant mesothelioma. Eur J Cancer 31A (1995) 1741-1747
19. Gordon G.J., Jensen R.V., Hsiao L.L., Gullans S.R., Blumenstock J.E., Ramaswamy S., Richards W.G., Sugarbaker D.J., and Bueno R. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62 (2002) 4963-4967
20. Gordon G.J., Jensen R.V., Hsiao L.L., Gullans S.R., Blumenstock J.E., Richards W.G., Jaklitsch M.T., Sugarbaker D.J., and Bueno R. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 95 (2003) 598-605
21. Pass H.I., Liu Z., Wali A., Bueno R., Land S., Lott D., Siddiq F., Lonardo F., Carbone M., and Draghici S. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10 (2004) 849-859
22. Gordon G.J., Rockwell G.N., Godfrey P.A., Jensen R.V., Glickman J.N., Yeap B.Y., Richards W.G., Sugarbaker D.J., and Bueno R. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11 (2005) 4406-4414
23. Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G., Glickman J.N., Aronson J.P., Pottorf B.J., Nitz M.D., Richards W.G., Sugarbaker D.J., and Bueno R. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166 (2005) 1827-1840
24. Lopez-Rios F., Chuai S., Flores R., Shimizu S., Ohno T., Wakahara K., Illei P.B., Hussain S., Krug L., Zakowski M.F., Rusch V., Olshen A.B., and Ladanyi M. Global gene expression profiling of pleural mesotheliomas: overexpression of Aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 15 66 (2006) 2970-2979
25. Nowak A.K., Lake R.A., Kindler H.L., and Robinson B.W. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 29 (2002) 82-96
26. Nygren J., Suhonen S., Norppa H., and Linnainmaa K. DNA damage in bronchial epithelial and mesothelial cells with and without associated crocidolite asbestos fibers. Environ Mol Mutagen 44 (2004) 477-482
27. Perera F.P. Environment and cancer: who are susceptible?. Science 278 (1997) 1068-1073
28. Nagel H., Schulten H.J., Gunawan B., Brinck U., and Fuzesi L. The potential value of comparative genomic hybridization analysis in effusion and fine needle aspiration cytology. Mod Pathol 15 (2002) 818-825
29. Vineis P., Schulte P., and McMichael A.J. Misconceptions about the use of genetic tests in populations. Lancet 357 (2001) 709-712
30. Pelin-Enlund K., Husgafvel-Pursiainen K., Tammilehto L., Klockars M., Jantunen K., Gerwin B.I., Harris C.C., Tuomi T., Vanhala E., Mattson K., and Linnainmaa K. Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis 11 (1990) 673-681
31. Pyrhonen S., Tiainen M., Rautonen J., Tammilehto L., Laasonen A., Mattson K., and Knuutila S. Comparison of DNA and karyotype ploidy in malignant mesothelioma. Cancer Genet Cytogenet 60 (1992) 8-13
32. Taguchi T., Jhanwar S.C., Siegfried J.M., Keller S.M., and Testa J.R. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53 (1993) 4349-4355
33. Flejter W.L., Li F.P., Antman K.H., and Testa J.R. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer 1 (1989) 148-154
34. Gibas Z., Li F.P., Antman K.H., Bernal S., Stahel R., and Sandberg A.A. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet 20 (1986) 191-201
35. Tammilehto L., Tuomi T., Tiainen M., Rautonen J., Knuutila S., Pyrhonen S., and Mattson K. Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients. Eur J Cancer 28A (1992) 1373-1379
36. Tiainen M., Kere J., Tammilehto L., Mattson K., and Knuutila S. Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: correlation between Southern blot and cytogenetic analyses. Genes Chromosomes Cancer 4 (1992) 176-182
37. Hagemeijer A., Versnel M.A., Van Drunen E., Moret M., Bouts M.J., van der Kwast T.H., and Hoogsteden H.C. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 47 (1990) 1-28
38. Popescu N.C., Chahinian A.P., and DiPaolo J.A. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res 48 (1988) 142-147
39. Tiainen M., Tammilehto L., Mattson K., and Knuutila S. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 33 (1988) 251-274
40. Shin H.J., Shin D.M., Tarco E., and Sneige N. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer 99 (2003) 233-239
41. Cora T., Acar H., Ceran S., and Bodur S. Analysis of chromosomes 9 and 11 aneuploidy frequency in pleural effusion of patients with and without malignancy: interphase FISH technique. Cancer Biol Ther 4 (2005) 248-251
42. Tiainen M., Tammilehto L., Rautonen J., Tuomi T., Mattson K., and Knuutila S. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 60 (1989) 618-626
43. Ascoli V., Scalzo C.C., Bruno C., Facciolo F., Lopergolo M., Granone P., and Nardi F. Familial pleural malignant mesothelioma: clustering in three sisters and one cousin. Cancer Lett 130 (1998) 203-207
44. Kivipensas P., Bjorkqvist A.M., Karhu R., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Kallioniemi O.P., and Knuutila S. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 89 (1996) 7-13
45. Bjorkqvist A.M., Tammilehto L., Nordling S., Nurminen M., Anttila S., Mattson K., and Knuutila S. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77 (1998) 260-269
46. Bjorkqvist A.M., Tammilehto L., Anttila S., Mattson K., and Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75 (1997) 523-527
47. Balsara B.R., Bell D.W., Sonoda G., De Rienzo A., du Manoir S., Jhanwar S.C., and Testa J.R. Comparative genomic hybridization and loss of heterozygosity analysis identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 59 (1999) 450-454
48. Knuutila S., Armengol G., Bjorkqvist A.M., el-Rifai W., Larramendy M.L., Monni O., and Szymanska J. Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet 100 (1998) 25-30
49. Krismann M., Muller K.M., Jaworska M., and Johnen G. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 197 (2002) 363-371
50. Krismann M., Adams H., Jaworska M., Muller K.M., and Johnen G. Patterns of chromosomal imbalances in benign solitary fibrous tumours of the pleura. Virchows Arch 437 (2000) 248-255
51. De Rienzo A., Jhanwar S.C., and Testa J.R. Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes Cancer 28 (2000) 337-341
52. Pylkkanen L., Sainio M., Ollikainen T., Mattson K., Nordling S., Carpen O., Linnainmaa H., and Husgafvel-Pursiainen K. Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep 9 (2002) 955-959
53. Jensen R.H., Tiirikainen M., You L., Ginzinger D., He B., Uematsu K., Xu Z., Treseler P., McCormick F., and Jablons D.M. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res 23 (2003) 2281-2289
54. Lee W.C., Balsara B., Liu Z., Jhanwar S.C., and Testa J.R. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res 56 (1996) 4297-4301
55. Bell D.W., Jhanwar S.C., and Testa J.R. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 57 (1997) 4057-4062
56. Bjorkqvist A.M., Wolf M., Nordling S., Tammilehto L., Knuuttila A., Kere J., Mattson K., and Knuutila S. Deletions at 14q in malignant mesothelioma detected by micro satellite marker analysis. Br J Cancer 81 (1999) 1111-1115
57. Decker H.J., Li F.P., Bixenman H.A., and Sandberg A.A. Chromosome 3 and 12p rearranged in a well-differentiated peritoneal mesothelioma. Cancer Genet Cytogenet 46 (1990) 135-137
58. Meloni A.M., Stephenson C.F., Li F.P., and Sandberg A.A. del(6q) as a possible primary change in malignant mesothelioma. Cancer Genet Cytogenet 59 (1992) 57-61
59. Center R., Lukeis R., Dietzsch E., Gillespie M., and Garson O.M. Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer 7 (1993) 47-53
60. Cheng J.Q., Jhanwar S.C., Lu Y.Y., and Testa J.R. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 53 (1993) 4761-4763
61. Cheng J.Q., Jhanwar S.C., Klein W.M., Bell D.W., Lee W.C., Altomare D.A., Nobori T., Olopade O.I., Buckler A.J., and Testa J.R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54 (1994) 5547-5551
62. Zeiger M.A., Gnarra J.R., Zbar B., Linehan W.M., and Pass H.I. Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer 11 (1994) 15-20
63. Lu Y.Y., Jhanwar S.C., Cheng J.Q., and Testa J.R. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer 9 (1994) 76-80
64. Xio S., Li D., Vijg J., Sugarbaker D.J., Corson J.M., and Fletcher J.A. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11 (1995) 511-515
65. Sandberg A.A., and Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft-tissue tumors. Mesothelioma. Cancer Genet Cytogenet 127 (2001) 93-110
66. Knuuttila A., Jee K.J., Taskinen E., Wolff H., Knuutila S., and Anttila S. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch 448 (2005) 135-141
67. Simon F., Johnen G., Krismann M., and Muller K.M. Chromosomal alterations in early stages of malignant mesotheliomas. Virchows Arch 447 (2005) 762-767
68. Kobashi Y., Matsushima T., and Irei T. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma. Respirology 10 (2005) 660-665
69. Whitson BA, Kratzke RA. Molecular pathways in malignant pleural mesothelioma. Cancer Lett; Oct 7, 2005[Epub ahead of print].
70. Rihn B.H., Mohr S., McDowell S.A., Binet S., Loubinoux J., Galateau F., Kieth G., and Leikauf G.D. Differential gene expression in mesothelioma. FEBS Lett 480 (2000) 95-100
71. Sun X., Dobra K., Bjornstedt M., and Hjerpe A. Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation 66 (2000) 181-188
72. Kettunen E., Nissen A.M., Ollikainen T., Taavitsainen M., Tapper J., Mattson K., Linnainmaa K., Knuutila S., and El-Rifai W. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 91 (2001) 492-496
73. Ramos-Nino M.E., Scapoli L., Martinelli M., Land S., and Mossman B.T. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 63 (2003) 3539-3545
74. Singhal S., Wiewrodt R., Malden L.D., Amin K.M., Matzie K., Friedberg J., Kucharczuk J.C., Litzky L.A., Johnson S.W., Kaiser L.R., and Albelda S.M. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9 (2003) 3080-3097
75. Hoang C.D., D'Cunha J., Kratzke M.G., Casmey C.E., Frizelle S.P., Maddaus M.A., and Kratzke R.A. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125 (2004) 1843-1852
76. Mohr S., Keith G., Galateau-Salle F., Icard P., and Rihn B.H. Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. Biochim Biophys Acta 1688 (2004) 43-60
77. Mohr S., Bottin M.C., Lannes B., Neuville A., Bellocq J.P., Keith G., and RihnMicrodissection B.H. mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 86 (2004) 13-19
78. Kettunen E., Nicholson A.G., Nagy B., Wikman H., Seppanen J.K., Stjernvall T., Ollikainen T., Kinnula V., Nordling S., Hollmen J., Anttila S., and Knuutila S. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis 26 (2005) 17-25
79. Wali A., Morin P.J., Hough C.D., Lonardo F., Seya T., Carbone M., and Pass H.I. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer 48 (2005) 19-29
80. Sun X., Wei L., Lidén J., Hui G., Dahlman-Wright K., Hjerpe A., and Dobra K. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 207 (2005) 91-101
81. Gerwin B.I., Lechner J.F., Reddel R.R., Roberts A.B., Robbins K.C., Gabrielson E.W., and Harris C.C. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res 47 (1987) 6180-6184
82. Langerak A.W., De Laat P.A., Van Der Linden-Van Beurden C.A., Delahaye M., Van Der Kwast T.H., Hoogsteden H.C., Benner R., and Versnel M.A. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 178 (1996) 151-160
83. Metheny-Barlow L.J., Flynn B., van Gijssel H.E., Marrogi A., and Gerwin B.I. Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 24 (2001) 694-702
84. Pass H.I., and Mew D.J. In vitro and in vivo studies of mesothelioma. J Biochem 24 Suppl (1996) 142-151
85. Zanella C.L., Posada J., Tritton T.R., and Mossman B.T. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 56 (1996) 5334-5338
86. Fitzpatrick D.R., Bielefeldt-Ohmann H., Himbeck R.P., Jarnicki A.G., Marzo A.L., and Robinson B.W. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity, and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11 (1994) 29-44
87. Jagadeeswaran R., Ma P.C., Seiwert T.Y., Jagadeeswaran S., Zumba O., Nallasura V., Ahmed S., Filiberti R., Paganuzzi M., Puntoni R., Kratzke R.A., Gordon G.J., Sugarbaker D.J., Bueno R., Janamanchi V., Bindokas V.P., Kindler H.L., and Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66 (2006) 352-361
88. Illei P.B., Rusch V.W., Zakowski M.F., and Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9 (2003) 2108-2113
89. Papp T., Schipper H., Pemsel H., Bastrop R., Muller K.M., Wiethege T., Weiss D.G., Dopp E., Schiffmann D., and Rahman Q. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18 (2001) 425-433
90. Pylkkanen L., Wolff H., Stjernvall T., Knuuttila A., Anttila S., and Husgafvel-Pursiainen K. Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch 444 (2004) 43-48
91. Prins J.B., Williamson K.A., Kamp M.M., Van Hezik E.J., Van der Kwast T.H., Hagemeijer A., and Versnel M.A. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75 (1998) 649-653
92. Wong L., Zhou J., Anderson D., and Kratzke R.A. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 38 (2002) 131-136
93. Illei P.B., Ladanyi M., Rusch V.W., and Zakowski M.F. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 99 (2003) 51-56
94. Dopp E., Poser I., and Papp T. Interphase fish analysis of cell cycle genes in asbestos-treated human mesothelial cells (HMC), SV40-transformed HMC (MeT-5A) and mesothelioma cells (COLO). Cell Mol Biol (Noisy-le-grand) 48 (2002) Online Pub:OL271-7
95. Kumar K., Rahman Q., Schipper H., Matschegewski C., Schiffmann D., and Papp T. Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. Oncol Rep 14 (2005) 743-750
96. Wikman H., and Kettunen E. Regulation of G1/S phase of the cell cycle and alterations in Rb-pathway in human lung cancer. Exp Rev Anticancer Ther 6 4 (2006) 515-530
97. Yang C.T., You L., Lin Y.C., Lin C.L., Mccormick F., and Jablons D.M. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res 23 (2003) 33-38
98. Hirao T., Bueno R., Chen C.J., Gordon G.J., Heilig E., and Kelsey K.T. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 23 (2002) 1127-1130
99. Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A., Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I., et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52 (1992) 2610-2615
100. Mor O., Yaron P., Huszar M., Yellin A., Jakobovitz O., Brok-Simoni F., Rechavi G., and Reichert N. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 16 (1997) 9-13
101. Husgafvel-Pursiainen K., Kannio A., Oksa P., Suitiala T., Koskinen H., Partanen R., Hemminki K., Smith S., Rosenstock-Leibu R., and Brandt-Rauf P.W. Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen 30 (1997) 224-230
102. Ni Z., Liu Y., Keshava N., Zhou G., Whong W., and Ong T. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 468 (2000) 87-92
103. Kitamura F., Araki S., Tanigawa T., Miura H., Akabane H., and Iwasaki R. Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos-PCR-SSCP and sequencing analyses of paraffin-embedded primary tumors. Ind Health 36 (1998) 52-56
104. Kitamura F., Araki S., Suzuki Y., Yokoyama K., Tanigawa T., and Iwasaki R. Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. Ind Health 40 (2002) 175-181
105. Creaney J., McLaren B.M., Stevenson S., Musk A.W., de Klerk N., Robinson B.W., and Lake R.A. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 84 (2001) 52-56
106. Hansteen I.L., Hilt B., Lien J.T., Skaug V., and Haugen A. Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report. Cancer Genet Cytogenet 70 (1993) 94-98
107. Taguchi T., Jhanwar S.C., Siegfried J.M., Keller S.M., and Testa J.R. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53 (1993) 4349-4355
108. Bianchi A.B., Mitsunaga S.I., Cheng J.Q., Klein W.M., Jhanwar S.C., Seizinger B., Kley N., Klein-Szanto A.J., and Testa J.R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92 (1995) 10854-10858
109. Sekido Y., Pass H.I., Bader S., Mew D.J., Christman M.F., Gazdar A.F., and Minna J.D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55 (1995) 1227-1231
110. Cheng J.Q., Lee W.C., Klein M.A., Cheng G.Z., Jhanwar S.C., and Testa J.R. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 24 (1999) 238-242
111. Schipper H., Papp T., Johnen G., Pemsel H., Bastrop R., Muller K.M., Wiethege T., Jaworska M., Krismann M., Schiffmann D., and Rahman Q. Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas. Int J Oncol 22 (2003) 1009-1017
112. Deguen B., Goutebroze L., Giovannini M., Boisson C., van der Neut R., Jaurand M.C., and Thomas G. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 77 (1998) 554-560
113. Baser M.E., De Rienzo A., Altomare D., Balsara B.R., Hedrick N.M., Gutmann D.H., Pitts L.H., Jackler R.K., and Testa J.R. Neurofibromatosis 2 and malignant mesothelioma. Neurology 59 (2002) 290-291
114. Fleury-Feith J., Lecomte C., Renier A., Matrat M., Kheuang L., Abramowski V., Levy F., Janin A., Giovannini M., and Jaurand M.C. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 22 (2003) 3799-3805
115. Lallemand D., Curto M., Saotome I., Giovannini M., and McClatchey A.I. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17 (2003) 1090-1100
116. Xiao G.H., Chernoff J., and Testa J.R. NF2: the wizardry of merlin. Genes Chromosomes Cancer 38 (2003) 389-399
117. Jung J.R., Kim H., Jeun S.S., Lee J.Y., Koh E.J., and Ji C. The phosphorylation status of Merlin is important for regulating the Ras-ERK pathway. Mol Cell 20 (2005) 196-200
118. Xiao G.H., Gallagher R., Shetler J., Skele K., Altomare D.A., Pestell R.G., Jhanwar S., and Testa J.R. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25 (2005) 2384-2394
119. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 49 Suppl 1 (2005) S3-S8
120. Peto J., Decarli A., La Vecchia C., Levi F., and Negri E. The European mesothelioma epidemic. Br J Cancer 79 (1999) 666-672